Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Shaftesbury boss invests £100,000

Fri, 04th Mar 2011 17:03

Shaftesbury chief executive Jonathan Lane has invested a further £100,000 in the property investor. Lane has bought 22,222 shares at 450p each. That takes his stake to 966,233 shares, which is worth £4.3m at the latest purchase price. Lane raised just over £99,000 from the sale of option shares last December. The property company is focused on London's theatre-land district and in February it said demand for its properties has remained healthy since the end of September. The company said investment activity in London's West End is returning to more normal levels, with Shaftesbury playing its part, having bought properties at a total cost of £30m since October. The group expects a further increase in activity over the next 12 months. Shaftesbury has tapped £486m of its £575m committed bank facilities. The average all-in cost of its bank debt at 31 January 2011 was 4.62%. Including its £61m of debenture borrowings, the overall cost of debt was 5%.Top Director Buys Shaftesbury (SHB) Director name: Mr Jonathan S LaneAmount purchased: 22,222 @ 450.00p Value: £99,999Diploma (DPLM) Director name: Mr I HendersonAmount purchased: 25,000 @ 276.00p Value: £69,000Development Securities (DSC) Director name: Mr Sarah BatesAmount purchased: 30,000 @ 203.00p Value: £60,900SThree (STHR) Director name: Mr Clayton BrendishAmount purchased: 12,000 @ 421.90p Value: £50,628CPP Group (CPP) Director name: Mr Duncan J McIntyreAmount purchased: 13,340 @ 297.00p Value: £39,620Xchanging (XCH) Director name: Mr Nigel RichAmount purchased: 50,000 @ 63.73p Value: £31,865International Ferro Metals Group (IFL) Director name: Mr Terence Vincent Coleman WillsteedAmount purchased: 100,000 @ 23.75p Value: £23,750Innovation Group (TIG) Director name: Mr Jane HallAmount purchased: 124,924 @ 15.85p Value: £19,800e-Therapeutics (ETX) Director name: Mr Steve SelfAmount purchased: 50,000 @ 36.50p Value: £18,250Mediwatch (MDW) Director name: Mr Philip G StimpsonAmount purchased: 550,000 @ 2.60p Value: £14,300Top Director Sells Serco Group (SRP) Director name: Mr Christopher R HymanAmount sold: 78,275 @ 582.76p Value: £456,155
More News
20 Mar 2018 16:14

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 21 March KingfisherFull Year ResultsAlpha FXFull Year In SportFull 22

Read more
9 Jan 2017 08:49

E-Therapeutics Hires Amgen Director As New Chief Executive

Read more
6 Oct 2016 11:23

DIRECTOR DEALINGS: e-Therapeutics Non-Executive Acquires Shares

Read more
14 Sep 2016 11:23

e-Therapeutics Development Director Steve Self To Step Down

Read more
13 Jul 2016 09:13

E-Therapeutics Chairman Takes On Executive Duties As CEO Steps Down

Read more
1 Jun 2016 08:03

e-Therapeutics Offer For Searchbolt Now Wholly Unconditional

Read more
25 May 2016 08:18

e-Therapeutics Focused On Validation Of Drug Discovery Platform

Read more
18 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
12 May 2016 11:13

DIRECTOR DEALINGS: E-Therapeutics Non-Executive Acquires Shares

Read more
11 May 2016 09:06

e-Therapeutics To Buy Searchbolt For GBP2.3 Million (ALLISS)

Read more
22 Mar 2016 11:40

E-Therapeutics Loss Widens As Active Projects Increase

Read more
15 Mar 2016 16:15

Earnings, Trading Statements Calendar - Week Ahead

Read more
15 Feb 2016 10:43

WINNERS & LOSERS SUMMARY: Reckitt Benckiser Results Please Investors

Read more
15 Feb 2016 09:45

E-Therapeutics depression drug trials miss targets

(ShareCast News) - Drug trials results for e-Therapeutics' depression treatment were not as successful as had been hoped, sending shares in the company sharply lower. Phase IIb clinical trials of the company's ETS6103 product did not achieve the aim of matching the efficacy of existing tricyclic ant

Read more
15 Feb 2016 08:20

E-Therapeutics Shares Drop As ETS6103 Trials Miss Primary Endpoint

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.